Geron Revealed Positive Imetelstat Results Amidst Data Concerns

Geron (NASDAQ: GERN ) revealed positive results from Imetelstat data this morning. Geron published that Imetelstat, a drug used to treat myelofibrosis, had an overall response rate of 44 percent. Further, the company wrote, “Among 13 patients with leukocytosis, 10 (77 percent) normalized their count or had >50 percent reduction.